Document is current

Article History

Received: 25 August 2025

Accepted: 23 September 2025

First Online: 9 October 2025

Declarations

:

: Kerstin Wolk has received research grants or contracts for clinical trials (payment to her institution), support for attending congresses and scientific awards, honoraria for consulting or participation on advisory boards or honoraria for lectures from one or more of the following: Celgene/Amgen, Celgene/Bristol Myers Squibb, Charité Research Organization, Flexopharm, Janssen-Cilag, Novartis Pharma, Sanofi–Aventis, TFS Trial Form Support, University hospital Magdeburg, European HS foundation (EHSF) and the Symposium on Hidradenitis Suppurativa Advances (SHSA); she also has a non-financial relationship with the HS task force of the German Consortium for Dermatological Research (ADF). Dagmar Wilsmann-Theis has been an advisor, speaker or investigator for Abbvie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Hexal, Incyte, Janssen-Cilag, Leo Pharma, Eli Lilly, Medac, Merck Sharp & Dohme Corp., MoonLake, Novartis, Pfizer and UCB Pharma. Nessr Abu Rached received funding, travel support and/or personal honoraria for lectures from Novartis Pharma, Janssen-Cilag GmbH and Johnson & Johnson that were independent of the work submitted. Rotraut Mössner has been an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials of the following companies: Abbvie, Allmirall, Biogen IDEC GmbH, Böhringer-Ingelheim, Celgene, Janssen-Cilag GmbH, Leo Pharma GmbH, Eli Lilly and Company, Merck Serono GmbH, MSD SHARP & DOHME GmbH, Novartis Pharma GmbH, Pfizer GmbH and UCB. Christian Kromer has been an advisor and/or received speaker’s honoraria from AbbVie, Janssen-Cilag, Novartis, Almirall, Boehringer Ingelheim and Dermapharm. Falk G. Bechara has received honoraria for participation on advisory boards, in clinical trials and/or as a speaker from AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, Acelyrin, Avalo, Beiersdorf, Boehringer Ingelheim Pharma GmbH & Co. KG, Celltrion, Dr. Wolff, Incyte Corporation, JanssenCilag GmbH,Johnson & Johnson, Merck, Mölnlycke, MoonLake, Novartis Pharma GmbH,Sanofi, Sitala and UCB Pharma. Katharina Assaf has received financial support (reimbursement of travel expenses and/or grants and/or participation in clinical trials) from the following companies: Abbvie, Almirall-Hermal, Amgen, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Incyte, Janssen-Cilag, Leo, Lilly, Novartis, Pfizer, Sanofi, Butterfly IQ and UCB. Wiebke K. Peitsch served as advisory board member for and/or obtained speakers’ honoraria from and/or received support for attending meetings from and/or obtained support for conferences at her institution from and/or participated in clinical trials by the following companies: AbbVie, ALK-Abello, Almirall Hermal, Amgen, Beiersdorf, Biogen, BMS, Boehringer Ingelheim, Celgene, Dermapharm, Dermasence, Galderma, GSK, Immunocore, Janssen-Cilag, Kyowa Kirin, L’Oréal, La Roche Posay, LEO Pharma, Lilly, MSD, Mylan, Novartis, Pfizer, Pierre Fabre, Regeneron, Roche, Sanofi, Sun Pharma, UCB Pharma and Viatris. Lisa C. Schneider obtained support for attending congresses and/or speaker`s honoraria from AbbVie, Janssen-Cilag and UCB Pharma. Durdana Gross was an advisor for, received speakers’ honoraria and/or grants from and/or participated in clinical trials for AbbVie, Almirall, Beiersdorf AG, Biogen, Bristol Myers Squibb, Celgene, Galderma, Janssen-Cilag GmbH, LEO Pharma, MSD, Pfizer, Sanofi-Aventis and UCB Pharma. Markus Friedrich received honoraria for participation on advisory boards, in clinical trials or as speaker from the following: Abbvie, Almirall, Bristol-Myers Squibb, Emphasis, Galderma, Janssen, LEO, Novartis, Sanofi Genzyme, UCB and Viatris. Khusru Asadullah received honoraria for participation on advisory boards, consultation, in clinical trials or as a speaker from: Abbvie, Almirall, Antabio, Bayer, Biofrontera, Celltrion, Bristol-Myers Squibb, Euroimmune, Emphasis, Emeritipharma, Galderma, Hexal, Janssen, La Roche-Posay, LEO, L’Oréal, Novartis, Parexel International, Pierre Fabre, Roxall, RG, Sandoz, Sanofi Genzyme, TFS Trial Form Support and UCB. Sylke Schneider-Burrus has been an advisor for and/or received speakers’ honoraria from and/or received grants from and/or participated in clinical trials of the following companies: Abbvie, Biogen IDEC GmbH, Böhringer-Ingelheim, Moonlake Immunotherapeutics, Novartis Pharma GmbH, Sanofi-Aventis and UCB. Georgios Kokolakis has received travel grants or honoraria from, or has been a consultant member of advisory boards and speakers bureaus for one or more of the following: AbbVie Deutschland GmbH & Co. KG, Actelion Pharmaceuticals Ltd., Almirall S.A., Amgen GmbH, Basilea Pharmaceutica Ltd., Bayer Schering Pharma AG, Biogen Idec GmbH, Celgene GmbH, Bristol-Myers Squibb GmbH & Co. KGaA, Hexal-Sandoz GmbH, Janssen-Cilag GmbH, Leo Pharma GmbH, Lilly Deutschland GmbH, MSD Sharp & Dohme GmbH, Novartis, Pfizer Deutschland GmbH, Sanofi Deutschland, Takeda, and UCB Pharma GmbH. Robert Sabat has received research grants or clinical trial contracts from AbbVie, Boehringer Ingelheim Pharma, Celgene/Amgen, Celgene/Bristol Myers Squibb, Charité Research Organization, CSL Behring, ICON, IQVIA RDS, Incyte, Janssen-Cilag/Janssen Research and Development, MoonLake Immunotherapeutics, Novartis, Parexel, Rheinischen Friedrich-Wilhelms-Universität Bonn, Sanofi Aventis, TFS and UCB Biopharma paid to their institution; honoraria for lectures, consulting or participation in advisory boards from AbbVie, Almirall Hermal, Amgen, Bayer Schering Pharma, Bruno Bloch Stiftung, Janssen-Cilag/Janssen Research and Development, Novartis, UCB Biopharma, Universitätsmedizin Greifswald, and Wundnetz Berlin-Brandenburg; and is a member of the International Psoriasis Council (unpaid) and speaker of the Psoriasis group of the German Consortium for Dermatological Research (unpaid). Giorgia Cugno, Andreas Happ, Valentina Siddi, Diana Kubitzki and Staffan Vandersee report no conflict of interest regarding this manuscript.

: The survey was approved by the ethics committee of the Charité University Medicine (reference number: EA4/205/22, positive vote from 8 February 2023) and registered in the German Register of Clinical Trials (identification number: DRKS00031572). It was conducted in accordance with the Declaration of Helsinki of 1964 and its later amendments. Participation was voluntary and anonymous, and all patients provided informed consent. The survey was conducted between May 2023 and July 2024.